Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smiths Group Plc LSE:SMIN London Ordinary Share GB00B1WY2338 ORD 37.5P
  Price Change % Change Share Price Shares Traded Last Trade
  41.50 2.7% 1,577.50 616,079 16:16:16
Bid Price Offer Price High Price Low Price Open Price
1,577.50 1,578.50 1,582.50 1,531.50 1,541.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Industrials 2,548.00 133.00 66.90 23.6 6,247
Last Trade Time Trade Type Trade Size Trade Price Currency
16:16:15 AT 46 1,577.50 GBX

Smiths (SMIN) Latest News

More Smiths News
Smiths Investors    Smiths Takeover Rumours

Smiths (SMIN) Discussions and Chat

Smiths Forums and Chat

Date Time Title Posts
16/11/202013:39Smiths Group _ ACTIVE INVESTORS CLUB (SMIN)98
22/4/201612:30Smiths Group221
31/1/200617:40Potential in these troubled times ?43
15/12/200510:55Numis upgrades1
26/9/200313:48Company about to face massive lawsuit re leaking sensitive info?1

Add a New Thread

Smiths (SMIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:16:151,577.5046725.65AT
16:16:151,577.502123,344.30AT
16:16:151,577.502323,659.80AT
16:16:151,577.502363,722.90AT
16:16:051,577.003856,071.45AT
View all Smiths trades in real-time

Smiths (SMIN) Top Chat Posts

DateSubject
04/12/2020
08:20
Smiths Daily Update: Smiths Group Plc is listed in the General Industrials sector of the London Stock Exchange with ticker SMIN. The last closing price for Smiths was 1,536p.
Smiths Group Plc has a 4 week average price of 1,378.50p and a 12 week average price of 1,287.50p.
The 1 year high share price is 1,778.50p while the 1 year low share price is currently 790p.
There are currently 396,022,479 shares in issue and the average daily traded volume is 1,005,447 shares. The market capitalisation of Smiths Group Plc is £6,247,254,606.23.
20/9/2019
06:51
broadwood: tWire.com - Industrial and medical products supplier Smiths booked a 19% fall in first-half profit and said a spin-off of its medical division was on track for the first half of 2020. Net profit, including one-off profits and losses from discontinued operations, fell to £227m, down from £279m on-year. Pre-tax profit from continuing operations rose 19% to £142m, as revenue from continuing operations rose 7% to £2.50bn. The company's operating margin rose 40 basis points to 17.1%. Smiths declared a full-year dividend of 45.90p per share, up 3% on-year. Its medical division returned to growth in the second half with revenue up 2%, delivering flat revenue for the year overall at £874m, in line with expectations. Headline operating profit in the division, however, fell 6% on an underying basis. Smiths said that it expected to notch further overall growth in the current financial year, weighted towards the first half that would result in a more even balance in overall performance between the first and second halves. 'We continue to build sustainable growth, paving the way to outperform our markets,' chief executive Andy Reynolds said. 'Importantly, this growth was coupled with enhanced margins, we have now delivered a 300 basis points margin improvement since 2016.' 'In addition, we continued to optimise our portfolio, with two acquisitions completed in the year.'
22/3/2019
07:32
broadwood: dustrial technology company Smiths Group booked a 13% fall in first-half profit as it revealed plans to spin off its under-performing medical business into a separately listed company. Pre-tax profit for the year through January declined to £174m, even as revenue rose 2% to £1.57bn. On an underlying basis, pre-tax profit fell by a more modest 1% to £216m. The company's operating margin fell 140 basis points to 13.5%. Smiths Group declared an interim dividend of 14.1p per share, up 2.2% on-year. The company said it expected to complete the demerger process during the first half of calendar 2020, conditional on shareholder approval. 'Smiths delivered another good performance in the first half with sustainable growth driven by John Crane, Flex-Tek and Smiths Interconnect,' chief executive Andy Reynolds Smith said. 'The strong results from these divisions were partly offset by the anticipated decline in Smiths Medical and the timing of deliveries in Smiths Detection, with both on track to deliver growth in the second half.' 'Today we have announced our plans for the separation of Smiths Medical to create two stronger companies each focusing on accelerating the execution of their plans and maximising the opportunities in their respective markets. 'We reaffirm our outlook for 2019.' 'We expect to continue to deliver sustainable underlying revenue growth of at least 2%, underpinned by current trading of our four industrial technology divisions and by the increasing contribution from new product launches in Smiths Medical.'
28/3/2018
07:15
mertles: Q&A from the recent conference call are well worth a listen. Was not surprised to see the share price recover somewhat on Friday.
18/8/2017
15:56
philanderer: Industrial technology firm Smiths Group has spent most of the past year offloading different businesses but the rumour doing the rounds in the City today was it could soon change tack. On a quiet Friday, the hearsay was that the FTSE 100 company has its eye on Accelerate Diagnostics, a little-known US medical technology firm worth $1.3 billion (£1 billion) on Nasdaq. The Arizona-based company is working towards commercialising technology which helps to diagnose infectious diseases sooner. Its shares rose 5% yesterday against a falling market with trading volumes much higher than normal. Although Smiths’ name is in the frame for a potential tilt, larger US groups have a head-start on it, sources said. Frontrunners for Accelerate are said to be Thermo Fisher Scientific and Boston Scientific — both are much larger and have far more firepower than Smiths, whose operations range from energy services to specialist medical devices. It has sold several non-core business over the past year to buoy the balance sheet. After recent falls, Accelerate’s shares are now changing hands for only $23 a pop. Gossips said Accelerate and its directors, who control a large chunk of the company, would hold out for at least $35 a share. Smiths and Accelerate said they do not comment on speculation. Shares in Smiths were down 10.15p to 1553p, tracking UK stocks lower as investors digested the Barcelona terror attack and the increasingly chaotic nature of Donald Trump’s presidency. London Ev Standard HTTPS://www.standard.co.uk/business/market-report-city-chatter-says-smiths-is-mulling-bid-for-us-firm-accelerate-diagnostics-a3614931.html
01/8/2017
10:18
corlis: SMIN 1,553 is starting to look like the only way is up in near future.
17/5/2017
00:01
philanderer: SMIN Smiths Group plc Smiths Detection Wins London Gatwick Airport Contract for CTX 9800 Hold Baggage Explosives Detection Systems CAMBRIDGE, England--(BUSINESS WIRE)-- - See more at: HTTPS://www.researchpool.com/company/smin-gb00b1wy2338-smiths-group-plc/press/smiths-group-plc-smin-smiths-detection-wins-london-gatwick-airport-contract-for-ctx-9800-hol#sthash.d7NmgUqB.dpuf
28/4/2017
12:51
martinthebrave: Good find Phil. You were looking a bit lonely here, so I thought I would let you know that you are not alone!! I am very optimistic for #SMIN and we should see significant share price upside in the next 12 months IMO........I Hold.
24/3/2017
20:36
philanderer: Telegraph market report: .....Elsewhere, forecast-beating half-year results lifted engineering firm Smiths to the top of the leaderboard, up 45p to £16.01. Operating profit rose 27pc to £277m boosted by cost cuts and growth in its detection unit. The group also maintained its full-year outlook. Following the upbeat results, Credit Suisse increased its price target from £16 to £17.40, adding its investment case “remains attractive”. HTTP://www.telegraph.co.uk/business/2017/03/24/pound-slips-125-ftse-100-drifts-lower-investors-eye-us-healthcare/
24/3/2017
08:17
broadwood: In at the start. Smiths Group has boosted its first-half pretax profit and revenue by double-digit percentages, as well as lifting its dividend, accompanied wiht an unchanged outlook for full-year 2017. "In the past six months we have made good progress to focus our portfolio and run our businesses better," said chief executive Andy Smith. He said strong cash conversion and improved margins across the group provided it with additional resources to invest for the future. "By laying the foundations for organic growth through targeted investments and by taking a disciplined approach to acquisitions and disposals, we are building a bigger, better and more focused Smiths," he added. Pretax profit was £248m, up 31% from £189m, with revenue coming in at £1.6bn, up 18% from £1.4bn. Interim dividend was 13.55p a share, up from 13.25p. "Overall, the outlook for 2017 is unchanged," said the CEO, Smith. "Group performance is expected to be slightly weighted towards the second half, albeit with a more balanced split between the first and second half than we saw last year." Smith expected some improvement in Smiths Medical's revenue performance in the second half. John Crane's first-fit end markets were expected to remain tough, somewhat counterbalanced by continued resilience in aftermarket. "We anticipate sales growth at Smiths Detection in the second half, albeit at lower levels than we saw in the first half, and margins will moderate given contract mix and investment in new products," he said. Smiths Interconnect and Flex-Tek were expected to continue to perform in line with the first half. "We expect cash conversion to continue to be strong as the rate of progress on inventory management improves. The depreciation of sterling is expected to provide a tailwind to reported revenue and operating profit, should current rates prevail."
08/2/2017
13:21
philanderer: Numis upgrades undervalued Smiths Group to 'buy' Numis has upgraded its rating on Smiths Group (SMIN) saying shares in the engineering company trade at a sector discount despite a turnaround. Analyst David Larkam raised his recommendation from ‘add’ to ‘buy’ with a target price of £18.10. The shares advanced 2% to close 30p up at £15.40. ‘Smiths shares have performed well since the new management team arrived in autumn 2015 but continue to trade at a discount to the UK general engineering sector,’ he said. ‘There are encouraging signs of de-conglomeration of the group while increased research and development suggests management are committed to reinvigorating growth. Delivering on these two planks could return us to the “old Smiths” as a predictable, solid growth, cash generative engineering group along with a premium rating which the group used to enjoy.’ HTTP://citywire.co.uk/money/the-expert-view-bp-smiths-group-and-bellway/a990376?re=44693&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&;utm_campaign=BulkEmail_Money_Daily#i=3
Smiths share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SMIN
Smiths
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 16:31:51